Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Neurological disorders are major contributors to death and disability worldwide. The pathology of injuries and disease processes includes a cascade of events that often involve molecular and cellular components of the immune system and their interaction with cells and structures within the central nervous system. Because of this, there has been great interest in developing neuroprotective therapeutic approaches that target neuroinflammatory pathways. Several neuroprotective anti-inflammatory agents have been investigated in clinical trials for a variety of neurological diseases and injuries, but to date the results from the great majority of these trials has been disappointing. There nevertheless remains great interest in the development of neuroprotective strategies in this arena. With this in mind, the complement system is being increasingly discussed as an attractive therapeutic target for treating brain injury and neurodegenerative conditions, due to emerging data supporting a pivotal role for complement in promoting multiple downstream activities that promote neuroinflammation and degeneration. As we move forward in testing additional neuroprotective and immune-modulating agents, we believe it will be useful to review past trials and discuss potential factors that may have contributed to failure, which will assist with future agent selection and trial design, including for complement inhibitors. In this context, we also discuss inhibition of the complement system as a potential neuroprotective strategy for neuropathologies of the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 1×
“Similar complement-mediated processes are indicated in other CNS diseases, such as Alzheimer’s disease (25) and Multiple Sclerosis (MS) (26).”
BackgroundGlutathione: overview of its protective roles, measurement, and biosynthesis
Forman, H. J., Zhang, H., & Rinna, A. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.006 · Cited by 2,636 · cited 1×
“Glutathione (GSH) is an endogenous antioxidant that protects cells from oxidative stress (189, 190), and reduced glutathione concentration and a simultaneous decrease in alpha-tocopherol levels in MS patients provided early evidence of elevated ROS during the active disease state (191).”
BackgroundKiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439 · cited 1×
“Similarly, Rituximab administration reduced inflammatory brain lesions along with a decrease in clinical relapses for 48 weeks (235) (NCT00097188).”
BackgroundKatan, M., & Luft, A. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1649503 · Cited by 2,137 · cited 1×
“Stroke is the second leading cause of death disability worldwide (32).”
BackgroundThe role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
Pathophysiology of traumatic brain injury
Werner, C., & Engelhard, K. (2007) · British Journal of Anaesthesia · doi:10.1093/bja/aem131 · Cited by 1,712
Inflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · cited 4×
“At diagnosis, it is estimated that almost a 3rd of dopaminergic neurons are already lost (242).”
BackgroundInfluentialEffects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 2×
“However, subsequent and larger clinical studies failed to show any benefit in patients treated with Coenzyme Q (317–319) (NCT00180037 and NCT00740714), although some studies did suggest a mild symptomatic relief due to its alternative effect as an antidepressive agent (316).”
BackgroundResultInflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739 · cited 1×
“Calcium Channel Blockers L-type calcium channel (LTCC) blockers showed efficacy in both MPTP and 6-OHDA animal models of PD (293, 294).”
BackgroundEffects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
Neurodegeneration by Activation of the Microglial Complement-Phagosome Pathway
Bodea, L.-G., Wang, Y., Linnartz-Gerlach, B., Kopatz, J., Sinkkonen, L., Musgrove, R., Kaoma, T., Muller, A., Vallar, L., Di Monte, D. A., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5002-13.2014 · Cited by 234
D‧Aniello, A., Di Fiore, M. M., Fisher, G. H., Milone, A., Seleni, A., D'Aniello, S., Perna, A. F., & Ingrosso, D. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.5.699 · Cited by 227
Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223 · cited 1×
“It is a peroxisome proliferatoractivated receptor gamma (PPARγ) agonist and alters the transcription of genes implicated in fatty acid oxidation, which result in metabolic changes (41).”
BackgroundStorch, A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.nct60005 · Cited by 205 · cited 1×
“Furthermore, a neuroprotective effect could not be determined since functional testing was performed while CoQ10 was present in patient serum, without confirmation of continued improvement following systemic decline of drug levels (318).”
BackgroundA further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
Ambrosi, G., Cerri, S., & Blandini, F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1149-z · Cited by 195 · cited 1×
“NMDA Receptor Antagonists Although glutamate is not the primary neurotransmitter implicated in PD, alterations of glutamatergic transmission contribute to the disease process through excitotoxicity (267, 268).”
BackgroundA phase II–III trial of olesoxime in subjects with amyotrophic lateral sclerosis
Lenglet, T., Lacomblez, L., Abitbol, J. L., Ludolph, A., Mora, J. S., Robberecht, W., Shaw, P. J., Pruss, R. M., Cuvier, V., Meininger, V., et al. (2014) · European Journal of Neurology · doi:10.1111/ene.12344 · Cited by 130 · cited 2×
“However, it failed two clinical trials as an add-on therapy for Riluzole for ALS (did not show a survival benefit) (163) (NCT00868166 and NCT01285583).”
BackgroundHou, L., Wang, K., Zhang, C., Sun, F., Che, Y., Zhao, X., Zhang, D., Li, H., & Wang, Q. (2018) · Redox Biology · doi:10.1016/j.redox.2017.09.017 · Cited by 104
Chen, Y., Wang, H., Ying, Z., & Gao, Q. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.051 · Cited by 63
Uranga, R. M., & Salvador, G. A. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2850341 · Cited by 48
Cited by
Mithaiwala, M. N., Santana-Coelho, D., Porter, G. A., & O’Connor, J. C. (2021) · Cells · doi:10.3390/cells10061548 · Cited by 190
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“Based on how they work, DMTs can be divided into a number of categories [37,76,83].”
BackgroundThe Gut Microbiota’s Role in Neurological, Psychiatric, and Neurodevelopmental Disorders
Charitos, I. A., Inchingolo, A. M., Ferrante, L., Inchingolo, F., Inchingolo, A. D., Castellaneta, F., Cotoia, A., Palermo, A., Scacco, S., & Dipalma, G. (2024) · Nutrients · doi:10.3390/nu16244404 · Cited by 44
“Finally, the confirmed action of GM derivatives on the hematological barrier can explain the enhancement of CNS inflammation in disorders of its composition [186].”
Malojirao, V. H., Vasquez, V., Kodavati, M., Mitra, J., Provasek, V., Voh, A. T. T., Liopo, A. V., Derry, P. J., Mikheev, A. M., Rostomily, R. C., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07983-3 · Cited by 13
Metadata
- Authors
- Mallah, K., Couch, C., Borucki, D. M., Toutonji, A., Alshareef, M., & Tomlinson, S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-10
- Volume
- 11
- Pages
- 2021-2021
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3085355901
- Cited by
- 100
- References
- 26
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.